iBio Inc Dossier
Qualitative Analysis
Business overview
iBio, Inc. is a preclinical-stage biotechnology company leveraging artificial intelligence (AI) and advanced computational biology to develop precision antibody therapies. The company's proprietary AI Drug Discovery Platform is designed to identify and optimize differentiated biologics for hard-to-drug targets, with a primary focus on cardiometabolic diseases, obesity, and cancer. Its core technology stack includes StableHu (AI antibody optimization), EngageTx (CD3 T-cell engager panel), ShieldTx (antibody masking), and AI epitope steering. Through a strategic collaboration with AstralBio, iBio is actively advancing its lead program, IBIO-600, a long-acting anti-myostatin antibody designed to promote muscle preservation and fat loss in obesity.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Development of a pipeline of highly differentiated, next-generation therapies for obesity and cardiometabolic diseases using AI-driven discovery. Key assets include IBIO-600 (anti-myostatin antibody) and IBIO-610 (activin E-targeting antibody) designed to induce fat-selective weight loss while preserving muscle mass.
Expected impact: Aims to deliver highly differentiated therapies that overcome the limitations of current treatments (such as muscle loss) in the fast-growing obesity market.
Development of a novel engineered amylin receptor agonist antibody program under the collaboration with AstralBio. Preclinical studies in obese rodent models demonstrated a 60% reduction in acute food intake, comparable to clinically advanced peptide therapies.
Expected impact: Provides a potential best-in-class therapeutic candidate offering quality weight loss, favorable gastrointestinal tolerability, and lean mass preservation.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Central to iBio's cardiometabolic and obesity pipeline [1.1.1]. The partnership, initiated in April 2024 and expanded in April 2025, covers five targets and has yielded key assets including IBIO-600, IBIO-610, and the amylin receptor program.
Terms: iBio paid an upfront fee of $750,000 in common stock for the IBIO-600 license. AstralBio is eligible for development and commercialization milestone payments of up to $28 million, plus low to mid-single-digit sublicense fees.